FC
NGM

FORA Capital’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

FORA Capital’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,625
Closed -$32K – 1058
2020
Q2 		$32K Buy
+1,625
New +$31.1K 0.01% 735

Other funds holding NGM

PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
GA
Greenspring Associates Owings Mills, Maryland $1.48B AUM 61.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
JRP
Jasper Ridge Partners Menlo Park, California $4.49B AUM 18.72% 1-Year Est. Return

FORA Capital's NGM Position: Q3 2020 in Review

FORA Capital sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q3 2020, closing a stake of 1,625 shares — an estimated $32K sold.

FORA Capital first reported a position in NGM in Q2 2020 and held it in 1 quarter. The position peaked at $32K in Q2 2020. 81 funds tracked by Wall St. Rank hold NGM as of Q3 2020.

  • FORA Capital reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • FORA Capital sold 1,625 NGM Biopharmaceuticals, Inc. Common Stock shares in Q3 2020, an estimated $32K.
  • FORA Capital first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2020 and held it in 1 quarter.
  • FORA Capital's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $32K in Q2 2020.
  • 81 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q3 2020.

Based on FORA Capital's 13F filing for Q3 2020, filed 13 Nov 2020.